|Chemical and physical data|
|Molar mass||617.51 g/mol g·mol−1|
|3D model (JSmol)|
TM-38837 is a small molecule inverse agonist/antagonist of the CB1 cannabinoid receptor, with peripheral selectivity. It is being developed for the treatment of obesity and metabolic disorders by 7TM Pharma. The company has announced phase I clinical trials.
TM-38837 is among the first of a new generation of cannabinoid receptor antagonist designed to avoid the central nervous system liabilities of the first generation CB1 receptor antagonists such as rimonabant.
|This cannabinoid related article is a stub. You can help Wikipedia by expanding it.|